| Lizenz: Creative Commons Namensnennung 4.0 International (12MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-351947
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.35194
Zusammenfassung
For over 60 years, hematopoietic stem cell transplantation (HSCT) has been the major curative therapy for several hematological and genetic disorders, but its efficacy is limited by the secondary disease called graft versus host disease (GvHD). Huge advances have been made in successful transplantation in order to improve patient quality of life and yet, complete success is hard to achieve. This ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik